David Denning

David Denning studied medicine at Guy’s Hospital, London, and graduated in 1980.[1] He then trained in internal medicine and infectious diseases in London and Glasgow.[1] Between 1985 and 1987 he was a Senior Registrar in Infectious Diseases at Northwick Park Hospital and Medical Research Council research laboratories, before a three-year fellowship in diagnostic microbiology and infectious diseases at Stanford University, which he completed in 1990.[1] He joined The University of Manchester as a Senior Lecturer in 1990.

He became professor of infectious diseases and global health and medical mycology in 2005 at Wythenshawe Hospital and the University of Manchester.[1] In 2009 he became the director of the UK's National Aspergillosis Centre in Manchester, which treats people with CPA.[2][3] He is the founding president, executive director and chief executive of the GAFFI, which focusses on the global impact of fungal disease.[1][4] Denning led the group that produced the first guidelines for CPA in 2016.[5] He chairs the editorial board of a website which focusses on aspergillus and he leads an organisation which provides education on fungal diseases.[2] Antifungal medications that he has contributed to research in include itraconazole, voriconazole, amphotericin B, caspofungin, and micafungin.[1] He founded two spinout biotechnology companies.[2] In 2020 he retired from clinical practice.[2]

• Denning, David W. (1998). "Invasive Aspergillosis". Clinical Infectious Diseases. 26 (4): 781–803. doi:10.1086/513943. ISSN 1058-4838. JSTOR 4481476. PMID 9564455. S2CID 9183178.
• Herbrecht, Raoul; Denning, David W.; Patterson, Thomas F.; Bennett, John E.; Greene, Reginald E.; Oestmann, Jörg-W.; Kern, Winfried V.; Marr, Kieren A.; Ribaud, Patricia; Lortholary, Olivier; Sylvester, Richard; Rubin, Robert H.; Wingard, John R.; Stark, Paul; Durand, Christine; Caillot, Denis; Thiel, Eckhard; Chandrasekar, Pranatharthi H.; Hodges, Michael R.; Schlamm, Haran T.; Troke, Peter F.; De Pauw, Ben (8 August 2002). "Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis". New England Journal of Medicine. 347 (6): 408–415. doi:10.1056/NEJMoa020191. hdl:2066/185528. ISSN 0028-4793. PMID 12167683. (Co-authored)
• Denning, David W. (4 October 2003). "Echinocandin antifungal drugs". The Lancet. 362 (9390): 1142–1151. doi:10.1016/S0140-6736(03)14472-8. ISSN 0140-6736. PMID 14550704. S2CID 35067894.
• "Hidden Killers: Human Fungal Infections". Science Translational Medicine. 4 (165): 165rv13. 19 December 2012. doi:10.1126/scitranslmed.3004404. ISSN 1946-6234. PMID 23253612. S2CID 3157271. (Co-authored)